Download PDF
Thromb Haemost 1974; 31(02): 339-345
DOI: 10.1055/s-0038-1649168
Original Article
Schattauer GmbH

Antithrombin III Deficiency in Maturity Onset Diabetes Mellitus and Atherosclerosis

R. N Banerjee
1   Department of Haematology and Nuclear Medicine, Safdarjang Hospital, New Delhi-16
,
A. L Sahni
1   Department of Haematology and Nuclear Medicine, Safdarjang Hospital, New Delhi-16
,
V Kumar
1   Department of Haematology and Nuclear Medicine, Safdarjang Hospital, New Delhi-16
,
M Arya
1   Department of Haematology and Nuclear Medicine, Safdarjang Hospital, New Delhi-16
› Author Affiliations
Further Information

Publication History

Received 26 September 1973

Accepted 26 November 1973

Publication Date:
29 June 2018 (online)

    Permissions and Reprints

Summary

Antithrombin III activity and thrombin times were assayed in maturity onset diabetics, atherosclerotic patients and normal subjects. There was a close correlation between the Antithrombin III activity and thrombin times in all three groups. Reductions in these measurements in diabetes mellitus and atherosclerosis, independent of thromboembolic phenomena, support the theory of Antithrombin III deficiency in these diseases.

 

  • References

  • 1 Banerjee R. N, Chakravarty B, Rao M. B. S, Sastry M. R. K, Sahni A. L. A study of Inter-relationsship in Diabetes mellitus and Atherosclerosis. Communication presented in XIth International Congress of Medicine, New Delhi, Octobe 1970(unpublished). 1970
    Google Scholar
  • 2 Banerjee R. N, Vijay Kumar Sahni A. L. Fibrinocoagulopathy in maturity onset diabetes mellitus and atherosclerosis. Communication presented in III Congress on Thrombosis, International Society on Thrombosis and Haemostasis. Washington D.C: 1972. a August 1972, Abstract 316
    Google Scholar
  • 3 Banerjee R. N, Vijay Kumar Sahni A. L. Plasma thrombin clotting time and plasma fibrinogen in diabetes mellitus and atherosclerosis. Indian Journal of Medical Research 1972; b 60: 1432
    PubMedGoogle Scholar
  • 4 Banerjee R. N, Sahni A. L. Vijay Kumar. Fibrinocoagulopathy in Maturity Onset Diabetes Mellitus and Atherosclerosis. Thrombosis et Diathesis Haemor-rhagica 1973; 30: 123
    PubMedGoogle Scholar
  • 5 Blombäck B, Blombäck M, Olsson P. Studies on thrombin inactivaltion in normal plasma serum and plasma fractions and its relation to heparin. Thrombosis et Diathesis Haemorrhagica 1963; 9: 368
    PubMedGoogle Scholar
  • 6 Ekberg O. Inherited antithrombin deficiency causing thrombophilia. Thrombosis et Diathesis Haemorrhagica 1965; 13: 516
    PubMedGoogle Scholar
  • 7 Ettinger M. G. Coagulation studies in cerebrovascular diseaseI. Hypercoagulability. Neurology 1964; 14: 907
    CrossrefPubMedGoogle Scholar
  • 8 Hensen A, Loeliger E. A. Antithrombin III, Its metabolism and its function in blood coagulation. Thrombosis et Diathesis Haemorrhagica 1963; Suppl (Suppl. 11) 9: 1
    PubMedGoogle Scholar
  • 9 Innerfield I, Angrist A. Plasma antithrombin determination. New test for cancer of pancreas associated with jaundice. American Journal of Medicine 1952; 223: 422
    CrossrefPubMedGoogle Scholar
  • 10 Schimpt K, Lenhard J. Untersuchungen zur Funktion des Antithrombin III. Thrombosis et Diathesis Haemorrhagica 1961; 6: 50
    PubMedGoogle Scholar
  • 11 Seegers W. H. Prothrombin ch 12. Cambridge, Mass: Harvard University Press, 1962. von Kaulla, E. and von Kaulla, K. N. (1967). Antithrombin III and Diseases, American Journal of Clinical Pathology 48, No. 1 1962; 69: 1962
    PubMedGoogle Scholar